Beron

Quick links to important sections

Beron

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beron

Property Description
Active ingredient Mirtazapine
Form Tablet, Orally Disintegrating Tablet (ODT), Oral Suspension
Pharmacological class Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)
Common use Mood stabilization and regulation in psychiatric practice
Origin Synthetic compound

Beron is a prescription-only medicine whose active ingredient is the synthetic compound Mirtazapine. It is fundamentally classified as an antidepressant, a type of psychoactive drug used for the overarching therapeutic purpose of stabilizing mood and regulating emotional balance, a role clinically recognized within psychiatric treatment protocols. As a single-ingredient product, its effects are entirely derived from Mirtazapine, which is designed to modulate key neurochemical activity in the central nervous system.


Functional Classification: The NaSSA Mechanism Principle

Beron belongs to a distinct pharmacological group known as an atypical antidepressant, specifically classified as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). This classification highlights the drug's unique mechanism, which differs from more common antidepressants by influencing both noradrenaline and serotonin neurotransmission through receptor antagonism. The overall goal of this mechanism is to facilitate more effective communication between brain cells, which is the foundational aim in managing persistent negative mood states.

Preclinical studies suggest Mirtazapine enhances central noradrenergic and serotonergic activity by acting as an antagonist at central presynaptic alpha2-adrenergic inhibitory autoreceptors and heteroreceptors. This unique dual action provides a specific pathway for affecting the neurochemical balance that governs mood.


Composition and Available Forms for Oral Administration

The medicinal product Beron contains only Mirtazapine as its active substance, integrated into a solid matrix along with necessary pharmaceutical excipients. It is intended for oral administration and is typically manufactured in multiple high-level dosage forms, including the conventional tablet and the orally disintegrating tablet (ODT), along with a potential oral suspension. The availability of forms such as the ODT provides a differentiating feature for patients who may have difficulty swallowing conventional tablets, ensuring flexibility in delivery of this medication.

What side effects are possible with Beron?

Possible Side Effects and Safety Information

The official safety profile of Beron (Mirtazapine) is documented by governmental regulatory authorities, classifying possible adverse reactions primarily by frequency and the body system affected. These classifications differentiate between highly reported effects and those that are rare but clinically critical.


Adverse Reaction Scope

Classification Examples of Reactions
Very Common Somnolence, increased appetite, weight gain, sedation, dry mouth, headache. These mainly affect the nervous system and metabolism.
Common Dizziness, lethargy, tremor, nausea, constipation, peripheral edema, myalgia, and arthralgia.
Rare Acute bone marrow depression (Agranulocytosis), elevated hepatic transaminases, aggression, and myoclonus.

Serious adverse reactions highlighted in official labeling include the potential for Suicidal thoughts and behavior, particularly in children, adolescents, and young adults. Other serious, though infrequent, risks include Serotonin Syndrome (when co-administered with other serotonergic agents) and severe blood disorders such as Neutropenia.


Regulatory Safety Notes

The label documents specific safety constraints, including the contraindication for use concurrently with or within two weeks of discontinuing a Monoamine Oxidase Inhibitor (MAOI). Caution is advised for patients with pre-existing severe hepatic or renal impairment, as clearance may be affected. The official documentation also notes somnolence and sedation may be more pronounced during the initial weeks of treatment, and older adults may have increased sensitivity to effects like orthostatic hypotension.

Overdose and Emergency Response

The official regulatory documents specify that an overdose of Beron (Mirtazapine) may present with documented manifestations primarily affecting the Central Nervous System and Cardiovascular System. These clinical signs include drowsiness, disorientation, impaired memory, excessive sedation, and tachycardia.

In severe overexposure scenarios, more serious outcomes have been reported, such as the development of Serotonin Syndrome, Coma, and, particularly in cases involving other substances, reports of QT prolongation and Torsades de Pointes. The potential for these life-threatening events requires the user to seek immediate medical attention for any suspected overdose, as strictly mandated by regulatory guidance.

Management is defined as symptomatic and supportive treatment, including the monitoring of vital functions and maintaining an adequate airway, as no specific antidote is known. Regulators emphasize that the risk of severe toxicity and fatalities increases significantly when Mirtazapine is ingested in a mixed overdose with other pharmacological agents. This context-specific constraint defines a high-risk situation that requires urgent medical intervention and observation.

Therapeutic Uses of Beron

Quick Facts

  • Therapeutic Domain: Component in various compounds investigated for potential health applications.
  • Primary Focus of Research: Supports metabolism of key minerals and hormones involved in bone structure.
  • Investigated Uses: Supports bone health maintenance and the healing process of tissues.

What Beron Treats: Main Uses and Benefits

Beron (Boron), a trace element, is investigated for its potential role in supporting human biological processes. While not classified as an essential human nutrient, available evidence suggests it may contribute to the proper metabolism of vitamins and minerals vital for bone development, such as calcium, magnesium, and vitamin D. This mechanism suggests a supportive effect in the maintenance of healthy bone structure.

Research has also explored Beron's influence on the activity of certain hormones, including estrogen and testosterone, which are implicated in bone health regulation. Additionally, some studies indicate a supportive capacity in the healing process of tissues, possibly through promoting the activity of enzymes in fibroblasts. These areas of investigation position Beron as a focus for potential use in complementary approaches to support bone maintenance and tissue regeneration, but these applications are not definitively established as therapeutic treatments.

Eligibility and Restrictions for Use

Official Eligibility and Restriction Profile

Beron, whose active ingredient is Mirtazapine, is officially approved for use in adults. Its eligibility profile contains absolute exclusions and conditions that require regulatory caution, strictly defined in government prescribing information.

Population Status Classification or Restriction
Approved Population Adults only (Primary indicated population).
Age Restriction Not approved for use in children and adolescents under 18 (Safety and efficacy are not established).
Absolute Exclusion Patients with known hypersensitivity to mirtazapine or those currently receiving, or having recently stopped, a Monoamine Oxidase Inhibitor (MAOI).
Form-Specific Exclusion Contraindicated for the Orally Disintegrating Tablet (ODT) formulation in patients with Phenylketonuria (PKU).

Conditions Requiring Caution and Conditional Use

Use of Beron is conditional on monitoring or caution in several specific populations, as documented by regulatory bodies:

  • Organ Function: Caution is required in patients with moderate to severe renal impairment or hepatic impairment, as drug clearance may be reduced.
  • Comorbidities: Caution is advised for those with a history of seizures, cardiovascular disease, or conditions that predispose to QT prolongation.
  • Manic History: Patients must be screened for a history of mania/hypomania; treatment must be discontinued if a manic phase is activated.
  • Reproductive Status: In pregnancy and during lactation, use is conditional and requires clinical assessment of potential benefits versus risks.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Beron's official regulatory documentation defines its interaction profile through key pharmacokinetic and pharmacodynamic relationships.

Contraindicated Combinations and Timing

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including specific agents like Linezolid and Methylene Blue, is formally contraindicated due to the risk of precipitating Serotonin Syndrome. A mandatory 14-day separation window is required when initiating or discontinuing an MAOI relative to Beron.

Exposure-Altering Interactions

Beron’s clearance is modulated by the CYP450 enzyme system, specifically CYP3A. Strong CYP3A inducers (e.g., Carbamazepine, Phenytoin) significantly increase clearance, leading to lower plasma concentrations. Conversely, strong CYP3A4 inhibitors (e.g., Ketoconazole, Cimetidine) decrease clearance, which results in elevated drug exposure.

Pharmacodynamic and Other Interactions

Additive effects are documented with other Serotonergic Drugs (including SSRIs, SNRIs, Triptans, and Lithium), increasing the risk of Serotonin Syndrome. Beron also has an additive CNS depressant effect when co-administered with Alcohol (Ethanol) or other CNS depressants, and the herbal product St. John’s Wort and the supplement Tryptophan are also listed as interacting substances. Additionally, the regulatory profile notes that Mirtazapine may increase the anticoagulant activities of Warfarin.

Population-Specific Notes

The drug’s clearance is officially documented as reduced in populations with hepatic impairment (approximately 30% decrease) and renal impairment (up to 50% decrease in severe cases).

Mechanism of Action

Beron's mechanism centers on three distinct actions in the central nervous system. First, the molecule acts as an antagonist at presynaptic alpha2-adrenergic receptors on nerve terminals. This blockade removes the inhibitory feedback signal, resulting in the disinhibition and subsequent increased release of both Noradrenaline and Serotonin into the synaptic space. This neurochemical augmentation increases the activity of central noradrenergic and serotonergic pathways. The second action establishes specificity: the molecule also blocks postsynaptic mathbf5-HT2 and mathbf5-HT3 receptors. This antagonism ensures that the increased Serotonin is directed away from these receptor subtypes, preferentially activating the mathbf5-HT1A pathway. This modulation shapes the downstream physiological consequences of the Serotonin increase. The third key action is the rapid antagonism of central mathbfH1 Histamine Receptors. This binding suppresses histamine-driven wakefulness pathways, leading to the physiological consequence of somnolence and is mechanistically linked to the regulation of appetite stimulation.

Dosage and Administration Information

Beron is administered exclusively via the oral route in several available forms, including the standard film-coated tablet, the orally disintegrating tablet (ODT), and a liquid suspension. The standard regimen for adults typically begins with an initial dose of 15 mg once daily, preferably taken in the evening prior to sleep, regardless of food intake.

The dosage must be regulated by a healthcare professional, with maintenance doses generally falling within the range of 15 mg to the maximum recommended daily dose of 45 mg. Any adjustment to the dose should be made cautiously and only after a minimum interval of one to two weeks to allow for sufficient response evaluation.

Specific administration constraints apply to the dosage forms. Standard tablets must be swallowed whole and should not be crushed or chewed. The ODT form requires careful handling with dry hands, placed immediately on the tongue to disintegrate, and swallowed with saliva. Treatment is typically maintained for several months following symptom resolution and must not be stopped abruptly; a gradual dose reduction (tapering) process is utilized to conclude treatment. Furthermore, caution and potential dose adjustments are necessary for older adults and patients with impaired hepatic or renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Beron (Mirtazapine)


The research evidence for Beron, which contains the active ingredient Mirtazapine, is primarily rooted in studies that explored outcomes related to symptoms studied in depression. The studies described in regulatory reviews focus on how Mirtazapine was evaluated in formal clinical settings for specific conditions.

Evidence for Use in Major Depressive Disorder (MDD)

The core evidence for Mirtazapine focuses on research exploring short-term symptom changes in Major Depressive Disorder. These randomized controlled trials (RCTs) involved adults with MDD, including cohorts relevant in evidence describing how symptoms are measured in relation to anxiety or sleep. Researchers used standardized clinical rating scales to monitor how symptoms change over time and to track the proportion of participants who met the criteria for a defined level of symptom change.

Studies on Maintenance and Preventing Relapse

Research was evaluated in studies exploring short-term symptom changes related to relapse. These maintenance studies used continuation trial designs, where participants who had achieved a measured response during the initial acute phase were observed over an intermediate follow-up duration. Studies monitored and described patterns related to outcomes capturing phases of heightened symptom activity in participants studied over longer intervals. Data for certain groups and for long-term outcomes extending significantly beyond one year remain insufficient.

Research on Augmentation Strategies for Depression

The research was evaluated in studies exploring the scenario of adding Mirtazapine to another existing antidepressant (augmentation) for adult patients who had not met the defined response criteria with initial single-drug treatment. These studies was evaluated in research exploring short-term symptom changes, measuring outcomes reflecting daily functioning or activity level. Findings were mixed across different trials, and certainty remains low regarding the consistency of measured outcomes for this approach across all study populations.

Evidence in Special Patient Populations

Specific research has explored Mirtazapine's use in certain special patient populations, such as older adults who presented with chronic sleep outcomes in conditions involving periods of heightened symptoms. These studies was studied for research contexts involving fluctuating or unstable symptoms, collecting patient-reported outcomes describing perceived discomfort. However, because the follow-up durations were typically short and the sample sizes were modest, evidence quality varies across studies. Long-term outcomes are not fully established for this population.

Evidence Gaps and Research Uncertainty

The research base primarily contains information from short-term and intermediate-term trials. Comparative evidence specifically addressing the durability of Mirtazapine against other classes of antidepressants over extended periods is lacking. Key research limitations include the fact that results apply only to the populations studied, and follow-up durations were limited. Study results reflect the specific conditions under which they were conducted and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Beron (FAQ)

Q: What is Beron used for besides the main condition?

According to official product information, Beron is primarily indicated for the treatment of Major Depressive Disorder (MDD). Regulatory research documents also note that the medicine has been studied for its use in augmentation strategies for depression and has been explored in special patient populations in connection with sleep-related outcomes.

Q: How quickly should someone expect Beron to start working?

While the full therapeutic effects of Beron may take several weeks to become noticeable, regulatory guidelines state that any adjustment to the dosage is typically made only after a minimum interval of one to two weeks. This initial period allows time to evaluate how the body is responding to the current dose.

Q: Are there any foods or drinks that should be avoided while taking Beron?

The official documentation indicates that Beron can be taken regardless of food intake. However, consumption of alcohol should be avoided because official records document an additive central nervous system (CNS) depressant effect when it is combined with the medicine.

Q: What is the difference between Beron and a placebo in clinical trials?

Studies used for regulatory approval involved randomized controlled trials (RCTs) to assess the medicine. In these trials, researchers tracked symptom changes between the group receiving Beron and a control group (placebo) to measure the proportion of participants who reached a defined level of clinical response.

Q: Can Beron be used by elderly patients?

Beron is approved for use in adults, which includes the elderly population. Regulatory information advises that caution and potential dosage adjustments are necessary for older adults. This group may also have increased sensitivity to specific effects, such as a drop in blood pressure when standing (orthostatic hypotension).

Q: Do studies exist for Beron use in children or adolescents?

Beron is not approved for use in children and adolescents under 18 because its safety and effectiveness have not been established in this age group. Regulatory documentation does include warnings about the risk of suicidal thoughts and behavior in young adults and adolescents, confirming this population was included in safety assessments.

Q: Does Beron interact with herbal supplements?

Official regulatory documents specifically list the herbal product St. John’s Wort as an interacting substance. Regulatory guidance emphasizes the necessity of disclosing all herbal supplements and over-the-counter products to a healthcare provider, as these substances can potentially alter the medicine's effects.

Q: Is there a generic version of Beron available?

Yes, Beron contains the active ingredient Mirtazapine. Mirtazapine is the regulatory name for the generic version of the medicine, and generic equivalents are generally available.

Q: Is Beron known to cause mood swings?

The official safety profile notes the risk of activating a manic phase in certain susceptible patients, and aggression is listed as a rare adverse reaction. Regulatory documentation states that treatment is required to be discontinued if a manic phase is activated.

Q: What is the most frequently reported side effect of Beron?

The official product information classifies Somnolence, increased appetite, weight gain, sedation, dry mouth, and headache as Very Common effects. While these are the most frequently reported category, regulatory documents do not usually specify an absolute single 'most frequent' event.

Q: Is Beron the same type of medicine as [similar drug name]?

Beron is classified as an atypical antidepressant and belongs to a distinct pharmacological group called the Noradrenergic and Specific Serotonergic Antidepressant (NaSSA) class. This classification highlights its unique mechanism of influencing both noradrenaline and serotonin neurotransmission, distinguishing it from other classes of antidepressants.

Q: What happens if a dose of Beron is missed?

The instructions for a missed dose described in official patient information generally state that a missed dose is taken when remembered. However, if the timing is near the next scheduled dose, the instruction is to skip the missed dose to prevent accidentally doubling the amount.

Q: Can Beron be taken with over-the-counter pain relievers?

Regulatory guidelines emphasize the importance of informing a healthcare provider of all medicines being taken, including over-the-counter (OTC) drugs, due to the potential for interactions. Non-steroidal pain relievers are generally not specifically listed as contraindications in the official documentation.

Q: Is Beron considered a strong medicine?

Beron is classified as a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). Its function is to modulate noradrenaline and serotonin activity in the central nervous system through a unique process called dual-receptor antagonism. The drug's effects are descriptive of its recognized action within this pharmacological class.

Q: Is Beron a controlled substance?

Beron is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent international bodies. It is available only as a prescription-only medicine because of its effects on the central nervous system and the necessity of medical supervision.

Q: What is the shelf life of Beron?

Official instructions state that Beron Oral Solution is required to be discarded six weeks after the first opening. Regulatory guidance also specifies that all forms should be stored at controlled room temperature, typically between 20 C and 25 C, and must be kept tightly closed, protected from light and moisture.

Q: Why is Beron available only by prescription?

As a psychoactive drug classified as an atypical antidepressant (NaSSA), Beron influences key neurochemical activity in the central nervous system. Because of its specific pharmacological effects and the requirement for professional monitoring, dose adjustment, and risk assessment, it is classified as a prescription-only medicine.

Q: Is Beron safe to take before driving or operating machinery?

Official regulatory documents caution patients about engaging in hazardous activities like driving or operating machinery. This is due to the potential for somnolence and sedation, which are common side effects that may impair judgment, thinking, and motor skills.

Q: Can I take Beron if I have high blood pressure?

Caution is officially advised for patients with a history of cardiovascular disease or conditions that predispose to certain heart rhythm changes (QT prolongation). While high blood pressure is not an absolute exclusion, the drug's profile highlights that cardiovascular status is a conditional consideration for use.

Q: What type of doctor usually prescribes Beron?

Beron is used for mood stabilization and regulation, a role clinically recognized within psychiatric treatment protocols. It is commonly prescribed by specialists in psychiatric practice or by primary care providers managing mental health conditions.

Q: Does Beron require special monitoring or blood tests?

Regulatory warnings advise patients about the rare, serious risk of developing blood disorders, such as Agranulocytosis. The official warnings state that if a patient develops signs of infection (such as fever or sore throat), immediate medical review is necessary, as this may require blood monitoring.

Q: Are there different strengths of Beron tablets?

Yes, official regulatory dosing documents describe an adult dosing range for Beron between a minimum of 15 mg and a maximum of 45 mg daily. Tablet strengths are typically available in multiple doses within this range to facilitate the required adjustment schedule.

Q: Is Beron affected by caffeine intake?

Caffeine is not explicitly listed in the major drug interaction tables for Beron found in official documentation. However, due to its effects on the central nervous system, official guidelines generally require the disclosure of all stimulants and non-prescription substances to a healthcare provider.

Q: What happens if I take Beron for longer than intended?

Official research evidence is based primarily on short-term and intermediate-term trials. Data regarding outcomes for long-term use extending significantly beyond one year are noted as currently insufficient, meaning the effects of extended, non-indicated use are not fully established in studies.

Q: Is Beron commonly used in other countries for the same purpose?

Yes, the active ingredient in Beron, Mirtazapine, is widely recognized and approved by major international regulatory bodies, including those in Europe, the UK, Canada, and Australia. It is used for the treatment of Major Depressive Disorder across these jurisdictions.

Q: Can Beron be taken by people with diabetes?

Diabetes is not listed as an absolute contraindication for use. However, regulatory documents state that Beron can cause metabolic effects, including increased appetite and weight gain. In patients with pre-existing metabolic conditions like diabetes, the official product information notes that close monitoring of these effects is a conditional requirement.

Q: What should I do if I think I'm having a rare side effect from Beron?

Regulatory guidance for severe or unusual symptoms, particularly those associated with serious risks (e.g., signs of infection or mood changes), states that immediate medical attention is necessary, and the healthcare provider must be informed. Adverse events can also be reported directly to public health regulatory authorities.

Q: Does Beron interact with common antibiotics?

Regulatory documents list the antibiotic Linezolid as strictly contraindicated due to its Monoamine Oxidase Inhibitor (MAOI) activity. Other common antibiotics that are strong modulators of the CYP3A enzyme system may alter the drug’s exposure and require caution or dose adjustment, based on the official interaction profile.

Q: Does Beron affect fertility?

The official regulatory profile notes that use during pregnancy and lactation is conditional and requires clinical assessment of potential benefits versus risks. Information regarding specific long-term effects on fertility (the ability to conceive) is not documented in the provided regulatory overview.

Q: Is Beron known to interact with birth control pills?

Beron's clearance is modulated by the CYP3A enzyme system, which also processes certain hormonal contraceptives. While hormonal birth control is not explicitly listed, the potential for drugs that interact with the CYP3A4 system to affect the effectiveness of birth control is a conditional consideration that requires clinical assessment.

How should Beron be stored and disposed of?

How to Store and Dispose of Beron?

Storage Requirements

Beron (Mirtazapine) must be stored under specific conditions to maintain stability. The tablets should be kept at controlled room temperature, generally between 20 C and 25 C. All forms must be protected from light and moisture. The product, including the oral solution, must not be stored above 25 C. The bottle of tablets should be kept tightly closed, and the Orally Disintegrating Tablets (ODT) must remain in the original blister pack until immediate use.

Stability and Child Safety

Beron Oral Solution should be discarded six weeks after the first opening. All medicines must be kept out of the sight and reach of children.

Disposal Instructions

Dispose of unused or expired Beron according to local regulations. The preferred method is using a drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance (e.g., used coffee grounds), place it in a sealed container, and discard it in the household trash. Do not dispose of medicine via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Beron found in:

A-Z Index: